- CureToday.com
- OncLive.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.
Michael Szarek, PhD | Authors
Articles
Michael Szarek, PhD, on Research Areas of Focus for Tivozanib in RCC
March 11, 2021
The expert from SUNY Downstate Medical Center spoke about areas of research for renal cell carcinoma which he believes deserve further attention.
Michael Szarek, PhD, on Treatment Advances With Tivozanib for RCC Going Forward
March 03, 2021
The expert from SUNY Downstate Medical Center highlighted areas in which he believes treatment for renal cell carcinoma will advance.
Michael Szarek, PhD, on the Next Steps for Tivozanib in Patients with Advanced RCC
March 01, 2021
An analysis revealed that as a third- or fourth-line treatment for advanced renal cell carcinoma, tivozanib significantly increased Q-TWiST compared with sorafenib, primarily through an increase in TWiST.
Michael Szarek, PhD, on the Outcomes of a Q-TWiST Analysis From the Phase 3 TIVO-3 Study
February 27, 2021
An analysis revealed that as a third- or fourth-line treatment for RCC, tivozanib significantly increased Q-TWiST compared with sorafenib, primarily through an increase in TWiST.
Michael Szarek, PhD, on the Rationale Behind Conducting a Q-TWiST Analysis of the Phase 3 TIVO-3 Study
February 22, 2021
A Q-TWiST analysis evaluated the use of tivozanib versus sorafenib among patients with advanced renal cell carcinoma included in the phase 3 TIVO-3 study.